Zevra Therapeutics, Inc.
ZVRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001434647
In the last 90 days, Zevra Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 159 institutions reported holding it in 13F filings for Q2 2026, worth $642.2M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 11, 2026
- $705.1M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $699.7K in total
- 2
- 13F holdersQ2 2026, +12 vs. previous quarter
- 159
- 13F valueReported value at the end of Q2 2026
- $642.2M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $106.5M
- +350.9% year over year
- Net income, FY2025
- $83.2M
- No comparable prior period
- Free cash flow, FY2025
- -$2.43M
- No comparable prior period
- Revenue, Q3 FY2026
- $37.8M
- +44.9% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net income for FY2025: $83.2M (78.2% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 6.56M
- Shares sold short
- Change
- +330.8K
- +5.3% vs. previous
- Days to cover
- 9.50
- At average daily volume
Superinvestors holding ZVRA, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding ZVRA at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Zevra Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 13, 2026 (view filing)4:24 PM ET | Oct 12 | 1 day | McFarlane Neil F.President and CEO | SSale | −20.0K | $11.25 | −$224.9K | −4.6%417.2K after | 10b5-1 |
| Aug 17, 2026 (view filing)4:32 PM ET | Aug 14 | 3 days | Thompson RahsaanChief Legal & Compliance | SSale | −42.7K | $11.13 | −$474.8K | −53.2%37.6K after | 10b5-1 |
| Aug 12, 2026 (view filing)4:16 PM ET | Aug 10 | 2 days | Watton Corey MichaelDirector | SSale | −12.3K | $11.25 | −$138.4K | −87.2%1.80K after | |
| Jun 23, 2026 (view filing) | Jun 22 | 1 day | Thompson RahsaanChief Legal & Compliance | SSale | −34.6K | $12.68 | −$438.2K | −30.1%80.2K after | 10b5-1 |
| May 13, 2026 (view filing) | May 11 | 2 days | Thompson RahsaanChief Legal & Compliance | SSale | −1.79K | $11.30 | −$20.3K | −3.6%48.1K after | 10b5-1 |
| Feb 10, 2026 (view filing) | Feb 9 | 1 day | McFarlane Neil F.President and CEO | SSale | −14.6K | $8.56 | −$125.2K | −3.6%387.2K after | 10b5-1 |
| Feb 4, 2026 (view filing) | Feb 3 | 1 day | Schafer JoshuaCCO | SSale | −10.5K | $9.19 | −$96.5K | −14.4%62.3K after | 10b5-1 |
| Feb 4, 2026 (view filing) | Feb 3 | 1 day | Sangiovanni Timothy J.SVP, Finance & Corp Controller | SSale | −3.00K | $9.18 | −$27.5K | −9.2%29.6K after | 10b5-1 |
| Feb 2, 2026 (view filing) | Jan 30 | 3 days | Schafer JoshuaCCO | SSale | −3.38K | $8.83 | −$29.8K | −8.3%37.4K after | 10b5-1 |
| Feb 2, 2026 (view filing) | Jan 30 | 3 days | Quartel Adrian WChief Medical Officer | SSale | −4.53K | $8.83 | −$40.0K | −31.8%9.72K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 159 holdersThe largest institutional positions in Zevra Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5,108,871 | $73.3M | 0.00% | +652,395+14.6% | Added |
| FMR LLC | 4,915,717 | $70.5M | 0.00% | +1,703,840+53.0% | Added |
| Woodline Partners LP | 4,785,771 | $68.6M | 0.21% | +1,334,828+38.7% | Added |
| Vanguard Capital Management LLC | 2,638,910 | $37.8M | 0.00% | +169,582+6.9% | Added |
| Nantahala Capital Management, LLC | 1,797,476 | $25.8M | 1.56% | −724,460−28.7% | Reduced |
| State Street Corp | 1,681,999 | $24.1M | 0.00% | +120,430+7.7% | Added |
| Geode Capital Management, LLC | 1,540,936 | $22.1M | 0.00% | +169,079+12.3% | Added |
| D. E. Shaw & Co., Inc. | 1,306,949 | $18.7M | 0.01% | +460,492+54.4% | Added |
| Qube Research & Technologies Ltd | 1,241,343 | $17.8M | 0.02% | +399,024+47.4% | Added |
| Morgan Stanley | 1,203,875 | $17.3M | 0.00% | +11,613+1.0% | Added |
Holders of 5% or more of ZVRA
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Zevra Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 9.40%5.56M shares | +1.10 ppfrom 8.30% | May 6, 20263 filings | Nov 5, 2026 | SEC |
| Woodline Partners LP | 13G/A | 8.10%4.79M shares | +1.90 ppfrom 6.20% | Nov 14, 20243 filings | Aug 14, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 7.60%4.08M shares | – | Feb 5, 20251 filing | Feb 5, 2025 | SEC |
| Vanguard Capital Management LLC | 13G | 5.11%3.02M shares | New | Jul 31, 20261 filing | Jul 31, 2026 | SEC |